Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Led by Brett Casper, a senior principal at Blue Fin Group, his agenda revolved around outlining the evolving orthodoxies for commercialization of ORD, CGT, and precision medicine; commercialization ...

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

The emerging biotech scene in Chicago has the potential to develop new treatments and technologies, but funding cuts from the ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.